New platform coming soon — AI-Based Analysis with Human-Generated Insights

Market News & Insights

American Analyst Ratings Updates: November 16th, 2026

American Analyst Ratings Updates: November 16th, 2026

Analyst Ratings (USA)

Applied Aerospace & Defense (AADX) — Jefferies Financial Group downgraded the stock to Hold and revised its price target from $20.00 to $10.00.

Aardvark Therapeutics (AARD) — Stifel Nicolaus set a price target of $2.00.

AbbVie (ABBV) — Barclays raised its price target from $325.00 to $335.00, maintaining an Overweight rating.

Ameris Bancorp (ABCB) — Raymond James Financial maintained its Market Perform rating.

AbCellera Biologics (ABCL) — Jefferies Financial Group maintained its Buy rating.

AbCellera Biologics (ABCL) — Piper Sandler raised its price target from $12.00 to $20.00, maintaining an Overweight rating.

Airbnb (ABNB) — Phillip Securities upgraded the stock to Hold and revised its price target from $158.00 to $184.00.

Absci (ABSI) — Guggenheim lowered its price target from $15.00 to $14.00, maintaining a Buy rating.

Array Digital Infrastructure (AD) — Royal Bank Of Canada lowered its price target from $40.00 to $33.00, maintaining a Sector Perform rating.

Array Digital Infrastructure (AD) — JPMorgan Chase & Co. lowered its price target from $45.00 to $43.00, maintaining an Overweight rating.

Agree Realty (ADC) — Wells Fargo & Company raised its price target from $79.00 to $81.00, maintaining an Overweight rating.

ADI Global Distribution Inc. Common Stock (ADIG) — Truist Financial lowered its price target from $24.00 to $11.00, maintaining a Hold rating.

Addus HomeCare (ADUS) — Royal Bank Of Canada raised its price target from $134.00 to $141.00, maintaining an Outperform rating.

Aetherion Technologies (AETR) — Royal Bank Of Canada raised its price target from $1.00 to $1.75, maintaining a Sector Perform rating.

Assurant (AIZ) — Morgan Stanley raised its price target from $330.00 to $360.00, maintaining an Overweight rating.

Arthur J. Gallagher & Co. (AJG) — Morgan Stanley raised its price target from $295.00 to $325.00, maintaining an Overweight rating.

Akebia Therapeutics (AKBA) — Piper Sandler issued a price target of $2.00, maintaining an Overweight rating.

Allstate (ALL) — JPMorgan Chase & Co. lowered its price target from $292.00 to $291.00, maintaining an Overweight rating.

Alumis (ALMS) — Oppenheimer issued a price target of $28.00, maintaining an Outperform rating.

Applied Materials (AMAT) — Freedom Broker lowered its price target from $530.00 to $490.00, maintaining a Buy rating.

Applied Materials (AMAT) — Susquehanna maintained its Positive rating.

Amgen (AMGN) — Barclays raised its price target from $400.00 to $430.00, maintaining an Equal Weight rating.

Amrize (AMRZ) — Jefferies Financial Group downgraded the stock to Underperform and revised its price target from $42.80 to $35.20.

Amrize (AMRZ) — UBS Group raised its price target from $42.00 to $46.00, maintaining a Neutral rating.

Anika Therapeutics (ANIK) — B. Riley Financial maintained its Buy rating and revised its price target from $23.00 to $17.00.

Annovis Bio (ANVS) — Roth Capital maintained its Buy rating with a price target of $3.00.

AON (AON) — Morgan Stanley raised its price target from $350.00 to $385.00, maintaining an Overweight rating.

AppLovin (APP) — Jefferies Financial Group set a price target of $500.00, maintaining a Buy rating.

Alexandria Real Estate Equities (ARE) — Mizuho lowered its price target from $60.00 to $50.00, maintaining an Outperform rating.

argenex (ARGX) — Piper Sandler raised its price target from $1,215.00 to $1,350.00, maintaining an Overweight rating.

Ascendis Pharma A/S (ASND) — Barclays raised its price target from $329.00 to $341.00, maintaining an Overweight rating.

ArriVent BioPharma (AVBP) — Guggenheim lowered its price target from $30.00 to $28.00, maintaining a Buy rating.

Atea Pharmaceuticals (AVIR) — Morgan Stanley raised its price target from $7.00 to $8.00, maintaining an Equal Weight rating.

Avalyn Pharma (AVLN) — Morgan Stanley lowered its price target from $57.00 to $53.00, maintaining an Overweight rating.

American Water Works (AWK) — Bank of America set a price target of $157.00, maintaining a Neutral rating.

Credicorp (BAP) — JPMorgan Chase & Co. raised its price target from $482.00 to $490.00, maintaining an Overweight rating.

Banco Bradesco (BBD) — Itau BBA Securities downgraded the stock to Market Perform.

Best Buy (BBY) — Telsey Advisory Group raised its price target from $95.00 to $110.00, maintaining an Outperform rating.

KE (BEKE) — Citigroup maintained its Buy rating.

KE (BEKE) — Jefferies Financial Group maintained its Buy rating.

BILL (BILL) — William Blair upgraded the stock to Outperform.

Bullish (BLSH) — Wells Fargo & Company lowered its price target from $35.00 to $28.00, maintaining an Equal Weight rating.

Belite Bio (BLTE) — Mizuho raised its price target from $221.00 to $230.00, maintaining an Outperform rating.

Belite Bio (BLTE) — Canaccord Genuity Group raised its price target from $303.00 to $314.00, maintaining a Buy rating.

Benitec Biopharma (BNTC) — Leerink Partners raised its price target from $18.00 to $18.27, maintaining an Outperform rating.

Benitec Biopharma (BNTC) — Wedbush raised its price target from $17.00 to $20.00, maintaining an Outperform rating.

BOX (BOX) — Citigroup raised its price target from $40.00 to $55.00, maintaining a Buy rating.

BP (BP) — Argus raised its price target from $50.00 to $53.00, maintaining a Buy rating.

Bragg Gaming Group (BRAG) — ATB Cormark Capital Markets downgraded the stock to Hold.

Brown & Brown (BRO) — Morgan Stanley raised its price target from $55.00 to $60.00, maintaining an Underweight rating.

Bending Spoons (BSP) — Bank of America set a price target of $38.00, maintaining an Underperform rating.

Bit Digital (BTBT) — B. Riley Financial issued a price target of $3.50, maintaining a Buy rating.

Peabody Energy (BTU) — UBS Group upgraded the stock to Buy and revised its price target from $27.50 to $22.00.

Burlington Stores (BURL) — Morgan Stanley lowered its price target from $432.00 to $381.00, maintaining an Overweight rating.

BrightView (BV) — Oppenheimer lowered its price target from $16.00 to $13.00, maintaining an Outperform rating.

KANZHUN (BZ) — JPMorgan Chase & Co. lowered its price target from $22.00 to $18.00, maintaining an Overweight rating.

Candel Therapeutics (CADL) — Citigroup lowered its price target from $26.00 to $20.00, maintaining a Buy rating.

Chubb (CB) — Morgan Stanley raised its price target from $360.00 to $380.00, maintaining an Equal Weight rating.

CBRE Group (CBRE) — Barclays lowered its price target from $183.00 to $161.00, maintaining an Overweight rating.

Cogent Communications (CCOI) — Wells Fargo & Company downgraded the stock to Underweight and revised its price target from $14.00 to $4.00.

Cardinal Infrastructure Group (CDNL) — Stifel Nicolaus downgraded the stock to Hold and revised its price target from $34.00 to $8.00.

COPT Defense Properties (CDP) — Wells Fargo & Company lowered its price target from $41.00 to $36.00, maintaining an Overweight rating.

CDW (CDW) — Barclays raised its price target from $148.00 to $164.00, maintaining an Equal Weight rating.

Codexis (CDXS) — Stephens maintained its Overweight rating with a price target of $5.00.

Ceva (CEVA) — Cfra upgraded the stock to Buy.

Citizens Financial Group (CFG) — Cantor Fitzgerald raised its price target from $78.00 to $80.00, maintaining an Overweight rating.

Cognex (CGNX) — Barclays lowered its price target from $85.00 to $76.00, maintaining an Overweight rating.

Cummins (CMI) — Morgan Stanley lowered its price target from $761.00 to $588.00, maintaining an Overweight rating.

Cannae (CNNE) — Royal Bank Of Canada downgraded the stock to Sector Perform and revised its price target from $17.00 to $18.00.

Compass Diversified (CODI) — Raymond James Financial maintained its Market Perform rating.

Collegium Pharmaceutical (COLL) — Barclays lowered its price target from $48.00 to $41.00, maintaining an Overweight rating.

Concentra Group Holdings Parent (CON) — Truist Financial maintained its Buy rating and revised its price target from $42.00 to $50.00.

Costco Wholesale (COST) — Northcoast Research downgraded the stock to Neutral.

Copart (CPRT) — Stephens maintained its Equal Weight rating with a price target of $35.00.

Salesforce (CRM) — UBS Group maintained its Buy rating.

Corsair Gaming (CRSR) — Wedbush raised its price target from $16.00 to $17.00, maintaining an Outperform rating.

CareTrust REIT (CTRE) — Mizuho lowered its price target from $45.00 to $44.00, maintaining an Outperform rating.

CareTrust REIT (CTRE) — Wells Fargo & Company raised its price target from $43.00 to $44.00, maintaining an Overweight rating.

CareTrust REIT (CTRE) — KeyCorp lowered its price target from $46.00 to $43.00, maintaining an Overweight rating.

CareTrust REIT (CTRE) — Citizens Jmp maintained its Market Outperform rating with a price target of $44.00.

Corteva (CTVA) — KeyCorp lowered its price target from $17.00 to $14.00, maintaining an Overweight rating.

City Therapeutics (CTY) — Jefferies Financial Group initiated coverage with a Strong-Buy rating.

Cousins Properties (CUZ) — Wells Fargo & Company raised its price target from $34.00 to $35.00, maintaining an Overweight rating.

CVR Energy (CVI) — Mizuho upgraded the stock to Neutral, with a price target of $47.00.

CommVault Systems (CVLT) — DA Davidson maintained its Buy rating with a price target of $210.00.

CommVault Systems (CVLT) — Stephens maintained its Overweight rating with a price target of $205.00.

CVS Health (CVS) — Royal Bank Of Canada lowered its price target from $113.00 to $108.00, maintaining an Outperform rating.

Cushman & Wakefield (CWK) — Barclays lowered its price target from $16.00 to $15.00, maintaining an Equal Weight rating.

Deere & Company (DE) — Raymond James Financial maintained its Outperform rating.

DeFi Technologies (DEFT) — B. Riley Financial maintained its Buy rating and revised its price target from $0.62 to $0.64.

Dell Technologies (DELL) — Morgan Stanley lowered its price target from $511.00 to $403.00, maintaining an Equal Weight rating.

Dell Technologies (DELL) — Citigroup lowered its price target from $600.00 to $550.00, maintaining a Buy rating.

Dolby Laboratories (DLB) — Rosenblatt Securities lowered its price target from $85.00 to $80.00, maintaining a Buy rating.

DLocal (DLO) — Susquehanna maintained its Positive rating.

Dollar Tree (DLTR) — UBS Group raised its price target from $150.00 to $165.00, maintaining a Buy rating.

Healthpeak Properties (DOC) — Mizuho lowered its price target from $24.00 to $23.00, maintaining an Outperform rating.

Healthpeak Properties (DOC) — Wells Fargo & Company raised its price target from $19.00 to $20.00, maintaining an Equal Weight rating.

DPC (DPC) — Morgan Stanley raised its price target from $43.00 to $47.00, maintaining an Equal Weight rating.

DPC (DPC) — Barclays raised its price target from $49.00 to $50.00, maintaining an Overweight rating.

Devon Energy (DVN) — Raymond James Financial maintained its Strong-Buy rating.

Eagle Point Credit (ECC) — B. Riley Financial lowered its price target from $4.50 to $4.00, maintaining a Buy rating.

Echostar (ECHO) — Citigroup raised its price target from $117.00 to $139.00, maintaining a Buy rating.

Encore Capital Group (ECPG) — Truist Financial downgraded the stock to Hold and revised its price target from $122.00 to $115.00.

Consolidated Edison (ED) — Bank of America set a price target of $106.00, maintaining an Underperform rating.

Equifax (EFX) — Needham & Company LLC raised its price target from $210.00 to $220.00, maintaining a Buy rating.

Equifax (EFX) — Mizuho raised its price target from $185.00 to $212.00, maintaining an Outperform rating.

Enovix (ENVX) — Canaccord Genuity Group issued a price target of $2.50, maintaining a Buy rating.

EOG Resources (EOG) — Citigroup raised its price target from $150.00 to $155.00, maintaining a Neutral rating.

EPR Properties (EPR) — Wells Fargo & Company raised its price target from $56.00 to $62.00, maintaining an Equal Weight rating.

Essential Properties Realty Trust (EPRT) — Wells Fargo & Company raised its price target from $30.00 to $32.00, maintaining an Overweight rating.

Eupraxia Pharmaceuticals (EPRX) — Wedbush maintained its Outperform rating.

Edwards Lifesciences (EW) — Wells Fargo & Company raised its price target from $113.00 to $121.00, maintaining an Overweight rating.

East West Bancorp (EWBC) — Cantor Fitzgerald raised its price target from $146.00 to $148.00, maintaining an Overweight rating.

Expand Energy (EXE) — The Goldman Sachs Group lowered its price target from $117.00 to $103.00, maintaining a Buy rating.

Extra Space Storage (EXR) — Barclays raised its price target from $172.00 to $173.00, maintaining an Overweight rating.

First BanCorp. (FBP) — UBS Group initiated coverage with a Neutral rating and a price target of $27.00.

Four Corners Property Trust (FCPT) — Wells Fargo & Company raised its price target from $22.00 to $23.00, maintaining an Equal Weight rating.

Adherex Technologies (FENC) — B. Riley Financial maintained its Buy rating and revised its price target from $18.00 to $19.00.

First Financial Bankshares (FFIN) — Cantor Fitzgerald lowered its price target from $34.00 to $33.00, maintaining a Neutral rating.

Figure Technology Solutions (FIGR) — Mizuho lowered its price target from $55.00 to $46.00, maintaining an Outperform rating.

Deep Fission (FISN) — ThinkEquity initiated coverage with a Buy rating.

Fiserv (FISV) — Robert W. Baird raised its price target from $70.00 to $85.00, maintaining an Outperform rating.

Fold (FLD) — Cantor Fitzgerald set a price target of $0.70, maintaining an Overweight rating.

FMC (FMC) — KeyCorp downgraded the stock to Sector Weight.

Federal Signal (FSS) — Raymond James Financial set a price target of $140.00, maintaining an Outperform rating.

Sensei Biotherapeutics (FTH) — HC Wainwright maintained its Buy rating with a price target of $60.00.

Sensei Biotherapeutics (FTH) — Needham & Company LLC maintained its Buy rating with a price target of $56.00.

FrontView REIT (FVR) — Wells Fargo & Company raised its price target from $20.00 to $22.00, maintaining an Overweight rating.

First Watch Restaurant Group (FWRG) — DA Davidson maintained its Buy rating with a price target of $17.00.

Gemini Space Station (GEMI) — Mizuho lowered its price target from $7.00 to $6.00, maintaining an Outperform rating.

Gemini Space Station (GEMI) — Rosenblatt Securities lowered its price target from $6.00 to $4.50, maintaining a Buy rating.

Gemini Space Station (GEMI) — Needham & Company LLC lowered its price target from $6.50 to $6.00, maintaining a Buy rating.

Gemini Space Station (GEMI) — The Goldman Sachs Group lowered its price target from $4.25 to $3.75, maintaining a Sell rating.

Gilead Sciences (GILD) — Barclays raised its price target from $145.00 to $160.00, maintaining an Equal Weight rating.

Glaukos (GKOS) — BTIG Research raised its price target from $234.00 to $252.00, maintaining a Buy rating.

Globe Life (GL) — TD Cowen raised its price target from $215.00 to $218.00, maintaining a Buy rating.

Gaming and Leisure Properties (GLPI) — Wells Fargo & Company lowered its price target from $40.00 to $39.00, maintaining an Equal Weight rating.

Galaxy Digital (GLXY) — Piper Sandler lowered its price target from $25.00 to $24.00, maintaining an Overweight rating.

Gold.com (GOLD) — DA Davidson maintained its Buy rating with a price target of $60.00.

Goosehead Insurance (GSHD) — Keefe, Bruyette & Woods lowered its price target from $66.00 to $60.00, maintaining an Outperform rating.

W.W. Grainger (GWW) — Morgan Stanley raised its price target from $1,400.00 to $1,590.00, maintaining an Equal Weight rating.

W.W. Grainger (GWW) — Barclays raised its price target from $1,172.00 to $1,355.00, maintaining an Underweight rating.

Hyatt Hotels (H) — Sanford C. Bernstein raised its price target from $202.00 to $231.00, maintaining an Outperform rating.

Haemonetics (HAE) — Citizens Jmp raised its price target from $115.00 to $144.00, maintaining a Market Outperform rating.

Haemonetics (HAE) — Citigroup maintained its Market Outperform rating.

Halozyme Therapeutics (HALO) — TD Cowen maintained its Buy rating.

Hasbro (HAS) — Wells Fargo & Company raised its price target from $100.00 to $115.00, maintaining an Equal Weight rating.

Hasbro (HAS) — Roth Capital maintained its Buy rating and revised its price target from $125.00 to $136.00.

Hasbro (HAS) — JPMorgan Chase & Co. raised its price target from $111.00 to $145.00, maintaining an Overweight rating.

HawkEye 360 (HAWK) — Morgan Stanley raised its price target from $25.00 to $26.00, maintaining an Overweight rating.

HudBay Minerals (HBM) — Barclays lowered its price target from $32.00 to $31.00, maintaining an Overweight rating.

Home Depot (HD) — Zelman & Associates downgraded the stock to Underperform.

Home Depot (HD) — Citigroup downgraded the stock to Sell.

Herbalife (HLF) — Wells Fargo & Company set a price target of $21.00.

Hilton Worldwide (HLT) — Sanford C. Bernstein raised its price target from $320.00 to $380.00, maintaining a Market Perform rating.

HMH (HMH) — Stifel Nicolaus lowered its price target from $28.00 to $25.00, maintaining a Buy rating.

HMH (HMH) — Citigroup maintained its Buy rating.

Hewlett Packard Enterprise (HPE) — Citigroup lowered its price target from $92.00 to $80.00, maintaining a Buy rating.

Hewlett Packard Enterprise (HPE) — Morgan Stanley lowered its price target from $72.00 to $64.00, maintaining an Overweight rating.

HP (HPQ) — Morgan Stanley raised its price target from $19.00 to $21.00, maintaining an Underweight rating.

Healthcare Realty Trust (HR) — Wells Fargo & Company raised its price target from $18.00 to $19.00, maintaining an Equal Weight rating.

Humana (HUM) — Royal Bank Of Canada upgraded the stock to Outperform and revised its price target from $415.00 to $563.00.

Humana (HUM) — Wells Fargo & Company downgraded the stock to Underweight.

Humana (HUM) — William Blair initiated coverage with an Outperform rating.

Humana (HUM) — Cantor Fitzgerald initiated coverage with an Overweight rating.

Humana (HUM) — ThinkEquity initiated coverage with a Buy rating.

Humana (HUM) — TD Cowen upgraded the stock to Buy.

Humana (HUM) — KeyCorp downgraded the stock to Sector Weight.

Hut 8 (HUT) — Piper Sandler lowered its price target from $123.00 to $115.00, maintaining an Overweight rating.

Hancock Whitney (HWC) — Keefe, Bruyette & Woods lowered its price target from $79.00 to $72.00, maintaining a Market Perform rating.

Installed Building Products (IBP) — Truist Financial raised its price target from $180.00 to $220.00, maintaining a Hold rating.

Installed Building Products (IBP) — Royal Bank Of Canada raised its price target from $194.00 to $215.00, maintaining a Sector Perform rating.

Intercontinental Exchange (ICE) — Argus raised its price target from $187.00 to $198.00, maintaining a Buy rating.

Intercontinental Hotels Group (IHG) — Sanford C. Bernstein raised its price target from $154.00 to $177.00, maintaining a Market Perform rating.

Illumina (ILMN) — Jefferies Financial Group set a price target of $235.00, maintaining a Hold rating.

Immunocore (IMCR) — BTIG Research maintained its Buy rating.

Immix Biopharma (IMMX) — HC Wainwright raised its price target from $25.00 to $27.00, maintaining a Buy rating.

Inhibrx Biosciences (INBX) — HC Wainwright lowered its price target from $245.00 to $220.00, maintaining a Buy rating.

Inter & Co. Inc. (INTR) — The Goldman Sachs Group lowered its price target from $9.00 to $8.00, maintaining a Buy rating.

Innoviz Technologies (INVZ) — The Goldman Sachs Group lowered its price target from $0.40 to $0.20, maintaining a Neutral rating.

Samsara (IOT) — Truist Financial lowered its price target from $48.00 to $41.00, maintaining a Hold rating.

iQIYI (IQ) — Jefferies Financial Group set a price target of $1.19, maintaining a Buy rating.

Ingersoll Rand (IR) — Melius Research upgraded the stock to Buy, with a price target of $113.00.

Quince Therapeutics (IRLA) — Citizens Jmp raised its price target from $77.00 to $86.00, maintaining a Market Outperform rating.

Itau Unibanco (ITUB) — JPMorgan Chase & Co. lowered its price target from $10.00 to $9.00, maintaining an Overweight rating.

Invivyd (IVVD) — BTIG Research maintained its Buy rating.

Janus Living (JAN) — Wells Fargo & Company raised its price target from $34.00 to $36.00, maintaining an Overweight rating.

Jade Biosciences (JBIO) — BTIG Research maintained its Buy rating.

Jade Biosciences (JBIO) — Guggenheim lowered its price target from $47.00 to $41.00, maintaining a Buy rating.

Jefferson Capital (JCAP) — Keefe, Bruyette & Woods raised its price target from $30.00 to $32.00, maintaining an Outperform rating.

Jones Lang LaSalle (JLL) — Barclays raised its price target from $401.00 to $404.00, maintaining an Equal Weight rating.

Kraft Heinz (KHC) — Barclays lowered its price target from $25.00 to $24.00, maintaining an Equal Weight rating.

KinderCare Learning Companies (KLC) — Barclays lowered its price target from $3.00 to $1.50, maintaining an Underweight rating.

Kennametal (KMT) — Morgan Stanley lowered its price target from $27.00 to $20.00, maintaining an Underweight rating.

Kinsale Capital Group (KNSL) — Morgan Stanley raised its price target from $350.00 to $400.00, maintaining an Equal Weight rating.

Kinetik (KNTK) — Wolfe Research upgraded the stock to Outperform.

Kinetik (KNTK) — Royal Bank Of Canada raised its price target from $58.00 to $62.00, maintaining an Outperform rating.

Coca Cola FEMSA (KOF) — Itau BBA Securities upgraded the stock to Strong-Buy.

Katapult (KPLT) — Stephens upgraded the stock to Overweight, with a price target of $15.00.

Kura Sushi USA (KRUS) — Northcoast Research downgraded the stock to Neutral.

Centrus Energy (LEU) — Cantor Fitzgerald initiated coverage with an Overweight rating and a price target of $130.00.

Lineage (LINE) — Truist Financial lowered its price target from $46.00 to $41.00, maintaining a Buy rating.

Lakefront Biotherapeutics American Depositary Shares (LKFT) — Morgan Stanley raised its price target from $26.00 to $27.00, maintaining an Equal Weight rating.

Eli Lilly and Company (LLY) — Barclays raised its price target from $1,400.00 to $1,550.00, maintaining an Overweight rating.

Lemonade (LMND) — Morgan Stanley lowered its price target from $48.00 to $45.00, maintaining an Equal Weight rating.

Lowe’s Companies (LOW) — Zelman & Associates downgraded the stock to Underperform.

Larimar Therapeutics (LRMR) — Wedbush lowered its price target from $11.00 to $9.00, maintaining an Outperform rating.

Intuitive Machines (LUNR) — Canaccord Genuity Group lowered its price target from $39.00 to $38.00, maintaining a Buy rating.

LiveOne (LVO) — Freedom Broker lowered its price target from $7.00 to $5.00, maintaining a Buy rating.

Lexeo Therapeutics (LXEO) — Raymond James Financial maintained its Strong-Buy rating.

Marriott International (MAR) — Sanford C. Bernstein raised its price target from $445.00 to $479.00, maintaining an Outperform rating.

MARA (MARA) — Piper Sandler lowered its price target from $11.00 to $10.00, maintaining an Overweight rating.

Mobility Global (MBGL) — Citigroup raised its price target from $23.00 to $25.00, maintaining a Neutral rating.

MercadoLibre (MELI) — Susquehanna maintained its Positive rating.

Milestone Pharmaceuticals (MIST) — Piper Sandler issued a price target of $3.00, maintaining an Overweight rating.

Martin Marietta Materials (MLM) — Morgan Stanley lowered its price target from $639.00 to $590.00, maintaining an Overweight rating.

3M (MMM) — Wells Fargo & Company raised its price target from $195.00 to $205.00, maintaining an Equal Weight rating.

Merit Medical Systems (MMSI) — Raymond James Financial set a price target of $104.00, maintaining an Outperform rating.

Monopar Therapeutics (MNPR) — Morgan Stanley raised its price target from $130.00 to $133.00, maintaining an Overweight rating.

Marsh & McLennan Companies (MRSH) — Morgan Stanley raised its price target from $190.00 to $215.00, maintaining an Equal Weight rating.

MSC Income Fund (MSIF) — Keefe, Bruyette & Woods lowered its price target from $15.50 to $15.00, maintaining an Outperform rating.

MasTec (MTZ) — Guggenheim lowered its price target from $518.00 to $335.00, maintaining a Buy rating.

SOLV Energy (MWH) — TD Cowen raised its price target from $35.00 to $37.00, maintaining a Buy rating.

KindlyMD (NAKA) — B. Riley Financial lowered its price target from $13.00 to $10.00, maintaining a Buy rating.

Navan (NAVN) — TD Cowen raised its price target from $30.00 to $32.00, maintaining a Buy rating.

National Bank (NBHC) — Hovde Group initiated coverage with an Outperform rating and a price target of $42.00.

Nebius Group (NBIS) — Citigroup lowered its price target from $265.00 to $215.00, maintaining a Buy rating.

National CineMedia (NCMI) — B. Riley Financial upgraded the stock to Buy and revised its price target from $2.50 to $3.00.

National CineMedia (NCMI) — National Bank Financial set a price target of $3.00.

NextDecade (NEXT) — TD Cowen raised its price target from $7.00 to $7.50, maintaining a Hold rating.

National Health Investors (NHI) — Wells Fargo & Company lowered its price target from $68.00 to $65.00, maintaining an Equal Weight rating.

NIQ Global Intelligence (NIQ) — Citigroup raised its price target from $16.00 to $19.50, maintaining a Neutral rating.

NIKE (NKE) — Cantor Fitzgerald maintained its Neutral rating with a price target of $38.00.

Nektar Therapeutics (NKTR) — Canaccord Genuity Group lowered its price target from $153.00 to $149.00, maintaining a Buy rating.

Newmark Group (NMRK) — Barclays lowered its price target from $20.00 to $14.00, maintaining an Overweight rating.

NNN REIT (NNN) — Wells Fargo & Company lowered its price target from $43.00 to $42.00, maintaining an Equal Weight rating.

Northrop Grumman (NOC) — BTIG Research maintained its Buy rating.

NeuroPace (NPCE) — Wolfe Research downgraded the stock to Hold.

NeuroPace (NPCE) — Mizuho lowered its price target from $22.00 to $12.00, maintaining an Outperform rating.

NeuroPace (NPCE) — HC Wainwright lowered its price target from $20.00 to $12.00, maintaining a Buy rating.

NRG Energy (NRG) — BMO Capital Markets lowered its price target from $147.00 to $124.00, maintaining a Market Perform rating.

Insperity (NSP) — JPMorgan Chase & Co. raised its price target from $38.00 to $45.00, maintaining an Underweight rating.

NetApp (NTAP) — Evercore maintained its Outperform rating.

Netskope (NTSK) — TD Cowen raised its price target from $19.00 to $25.00, maintaining a Buy rating.

NETSTREIT (NTST) — Wells Fargo & Company raised its price target from $20.00 to $21.00, maintaining an Overweight rating.

Nucor (NUE) — UBS Group upgraded the stock to Buy and revised its price target from $256.00 to $307.00.

NVIDIA (NVDA) — Mizuho lowered its price target from $250.00 to $220.00, maintaining an Outperform rating.

NVIDIA (NVDA) — TD Cowen lowered its price target from $275.00 to $200.00, maintaining a Buy rating.

NVIDIA (NVDA) — UBS Group set a price target of $240.00, maintaining a Buy rating.

NVIDIA (NVDA) — CLSA initiated coverage with a Moderate Buy rating.

NVIDIA (NVDA) — CLSA set a price target of $255.00, maintaining an Outperform rating.

Realty Income (O) — Wells Fargo & Company raised its price target from $59.00 to $61.00, maintaining an Equal Weight rating.

OFG Bancorp (OFG) — UBS Group initiated coverage with a Sell rating and a price target of $50.00.

Once Upon A Farm (OFRM) — Barclays lowered its price target from $19.00 to $11.00, maintaining an Equal Weight rating.

Omega Healthcare Investors (OHI) — Royal Bank Of Canada raised its price target from $51.00 to $52.00, maintaining a Sector Perform rating.

Omega Healthcare Investors (OHI) — Mizuho raised its price target from $46.00 to $49.00, maintaining a Neutral rating.

Omega Healthcare Investors (OHI) — Wells Fargo & Company raised its price target from $46.00 to $49.00, maintaining an Equal Weight rating.

Orion180 Insurance Group (OIG) — Raymond James Financial maintained its Market Perform rating.

Omada Health (OMDA) — JPMorgan Chase & Co. lowered its price target from $30.00 to $25.00, maintaining an Overweight rating.

Ondas (ONDS) — Stifel Nicolaus lowered its price target from $18.00 to $15.00, maintaining a Buy rating.

Orrstown Financial Services (ORRF) — Raymond James Financial maintained its Market Perform rating.

Blue Owl Technology Finance (OTF) — Keefe, Bruyette & Woods lowered its price target from $12.00 to $11.50, maintaining a Market Perform rating.

Ovintiv (OVV) — JPMorgan Chase & Co. set a price target of $84.00.

Blue Owl Capital (OWL) — Mizuho initiated coverage with an Outperform rating and a price target of $13.00.

Owlet (OWLT) — TD Cowen lowered its price target from $10.00 to $4.00, maintaining a Buy rating.

Everpure (P) — Morgan Stanley raised its price target from $137.00 to $142.00, maintaining an Overweight rating.

Everpure (P) — Wedbush set a price target of $130.00, maintaining an Outperform rating.

PACS Group (PACS) — Royal Bank Of Canada raised its price target from $57.00 to $64.00, maintaining an Outperform rating.

Palo Alto Networks (PANW) — Cantor Fitzgerald maintained its Overweight rating with a price target of $425.00.

Palo Alto Networks (PANW) — TD Cowen maintained its Buy rating with a price target of $440.00.

Pro-Dex (PDEX) — Ascendiant Capital Markets raised its price target from $74.00 to $80.00, maintaining a Buy rating.

Principal Financial Group (PFG) — UBS Group initiated coverage with a Sell rating and a price target of $50.00.

Precigen (PGEN) — B. Riley Financial maintained its Buy rating and revised its price target from $12.00 to $11.00.

Palantir Technologies (PLTR) — Deutsche Bank set a price target of $248.00.

Palantir Technologies (PLTR) — Barclays set a price target of $248.00.

Palantir Technologies (PLTR) — Phillip Securities upgraded the stock to Strong-Buy.

Praxis Precision Medicines (PRAX) — Guggenheim raised its price target from $800.00 to $1,050.00, maintaining a Buy rating.

Praxis Precision Medicines (PRAX) — Robert W. Baird raised its price target from $514.00 to $568.00, maintaining an Outperform rating.

Prime Medicine (PRME) — HC Wainwright maintained its Buy rating with a price target of $8.00.

Palvella Therapeutics (PVLA) — Leerink Partners initiated coverage with an Outperform rating and a price target of $228.00.

Q2 (QTWO) — JPMorgan Chase & Co. raised its price target from $76.00 to $82.00, maintaining an Overweight rating.

QXO (QXO) — Raymond James Financial set a price target of $21.00, maintaining an Outperform rating.

Roblox (RBLX) — Piper Sandler maintained its Neutral rating with a price target of $52.00.

RideNow Group (RDNW) — DA Davidson lowered its price target from $8.00 to $5.00, maintaining a Neutral rating.

Real REMAX Group (REAX) — Freedom Broker lowered its price target from $40.00 to $25.00, maintaining a Buy rating.

Replimune Group (REPL) — Piper Sandler raised its price target from $14.00 to $27.00, maintaining an Overweight rating.

Rithm Capital (RITM) — Piper Sandler maintained its Overweight rating.

Rivian Automotive (RIVN) — Citigroup lowered its price target from $18.00 to $14.50, maintaining a Neutral rating.

Rivian Automotive (RIVN) — DA Davidson maintained its Neutral rating with a price target of $15.00.

Suncrete (RMIX) — Robert W. Baird lowered its price target from $17.00 to $9.00, maintaining an Outperform rating.

Roivant Sciences (ROIV) — Guggenheim raised its price target from $46.00 to $48.00, maintaining a Buy rating.

Ross Stores (ROST) — Morgan Stanley raised its price target from $234.00 to $235.00, maintaining an Equal Weight rating.

Rapid Micro Biosystems (RPID) — Lake Street Capital downgraded the stock to Hold, with a price target of $0.75.

Revvity (RVTY) — KeyCorp maintained its Overweight rating with a price target of $200.00.

Revvity (RVTY) — JPMorgan Chase & Co. raised its price target from $160.00 to $165.00, maintaining a Neutral rating.

Recursion Pharmaceuticals (RXRX) — JPMorgan Chase & Co. lowered its price target from $10.00 to $7.00, maintaining an Overweight rating.

Ryan Specialty (RYAN) — Morgan Stanley raised its price target from $50.00 to $55.00, maintaining an Overweight rating.

Sana Biotechnology (SANA) — Citigroup issued a price target of $11.00, maintaining a Buy rating.

Sabra Healthcare REIT (SBRA) — Mizuho raised its price target from $21.00 to $22.00, maintaining a Neutral rating.

Sabra Healthcare REIT (SBRA) — Wells Fargo & Company raised its price target from $21.00 to $23.00, maintaining an Overweight rating.

SolarEdge Technologies (SEDG) — Wells Fargo & Company lowered its price target from $36.00 to $26.00, maintaining an Equal Weight rating.

Super Group (SGHC) (SGHC) — Wells Fargo & Company initiated coverage with an Equal Weight rating and a price target of $13.00.

Somnigroup International (SGI) — The Goldman Sachs Group initiated coverage with a Neutral rating and a price target of $72.00.

Sigma Lithium (SGML) — JPMorgan Chase & Co. lowered its price target from $11.00 to $7.00, maintaining an Overweight rating.

SiteOne Landscape Supply (SITE) — Stifel Nicolaus raised its price target from $102.00 to $108.00, maintaining a Hold rating.

J. M. Smucker (SJM) — JPMorgan Chase & Co. raised its price target from $149.00 to $150.00, maintaining an Overweight rating.

Skyward Specialty Insurance Group (SKWD) — TD Cowen raised its price target from $65.00 to $69.00, maintaining a Hold rating.

Summit Therapeutics (SMMT) — Barclays lowered its price target from $20.00 to $18.00, maintaining an Equal Weight rating.

Summit Therapeutics (SMMT) — Citigroup lowered its price target from $43.00 to $42.00, maintaining a Buy rating.

Semtech (SMTC) — UBS Group lowered its price target from $230.00 to $200.00, maintaining a Buy rating.

Semtech (SMTC) — Morgan Stanley lowered its price target from $205.00 to $176.00, maintaining an Equal Weight rating.

Spectrum Brands (SPB) — Wells Fargo & Company raised its price target from $85.00 to $87.00, maintaining an Equal Weight rating.

SpaceX (SPCX) — Royal Bank Of Canada maintained its Outperform rating with a price target of $225.00.

SpaceX (SPCX) — Pivotal Research maintained its Buy rating.

SpaceX (SPCX) — Raymond James Financial maintained its Strong-Buy rating.

SpaceX (SPCX) — Sanford C. Bernstein maintained its Outperform rating.

SpaceX (SPCX) — Piper Sandler maintained its Neutral rating.

SpaceX (SPCX) — The Goldman Sachs Group maintained its Buy rating.

SiriusPoint (SPNT) — Raymond James Financial maintained its Market Perform rating.

SPX Technologies (SPXC) — TD Cowen upgraded the stock to Buy and revised its price target from $225.00 to $200.00.

Stag Industrial (STAG) — Wells Fargo & Company raised its price target from $38.00 to $39.00, maintaining an Equal Weight rating.

Stagwell (STGW) — Stonex Financial upgraded the stock to Strong-Buy.

Stagwell (STGW) — StoneX upgraded the stock to Buy, with a price target of $15.00.

Neuronetics (STIM) — William Blair initiated coverage with an Outperform rating.

Steel Dynamics (STLD) — UBS Group lowered its price target from $276.00 to $257.00, maintaining a Neutral rating.

Stantec (STN) — Stifel Nicolaus downgraded the stock to Hold.

BBB Foods (TBBB) — Itau BBA Securities downgraded the stock to Market Perform, with a price target of $74.00.

Telephone and Data Systems (TDS) — JPMorgan Chase & Co. lowered its price target from $48.00 to $45.00, maintaining an Overweight rating.

Tidewater (TDW) — Barclays lowered its price target from $91.00 to $88.00, maintaining an Equal Weight rating.

Telecom Argentina Stet – France Telecom (TEO) — UBS Group lowered its price target from $16.50 to $15.00, maintaining a Buy rating.

Target (TGT) — Jefferies Financial Group maintained its Buy rating.

Target Hospitality (TH) — Morgan Stanley lowered its price target from $25.00 to $21.00, maintaining an Overweight rating.

Target Hospitality (TH) — Oppenheimer lowered its price target from $27.00 to $22.00, maintaining an Outperform rating.

The Hanover Insurance Group (THG) — Morgan Stanley raised its price target from $235.00 to $250.00, maintaining an Equal Weight rating.

TJX Companies (TJX) — Morgan Stanley lowered its price target from $178.00 to $166.00, maintaining an Overweight rating.

TriNet Group (TNET) — JPMorgan Chase & Co. raised its price target from $50.00 to $55.00, maintaining an Underweight rating.

Targa Resources (TRGP) — Stifel Nicolaus raised its price target from $335.00 to $340.00, maintaining a Buy rating.

Trustmark (TRMK) — Keefe, Bruyette & Woods raised its price target from $50.00 to $54.00, maintaining a Market Perform rating.

TransUnion (TRU) — Mizuho raised its price target from $74.00 to $78.00, maintaining a Neutral rating.

TWFG (TWFG) — Morgan Stanley raised its price target from $31.00 to $32.00, maintaining an Overweight rating.

Twist Bioscience (TWST) — Barclays lowered its price target from $215.00 to $130.00, maintaining an Overweight rating.

Texas Roadhouse (TXRH) — Gordon Haskett upgraded the stock to Buy, with a price target of $220.00.

Travelzoo (TZOO) — Ascendiant Capital Markets lowered its price target from $20.00 to $18.00, maintaining a Buy rating.

United Dominion Realty Trust (UDR) — Zelman & Associates upgraded the stock to Outperform, with a price target of $41.25.

Ulta Beauty (ULTA) — BMO Capital Markets raised its price target from $580.00 to $665.00, maintaining a Market Perform rating.

USA Rare Earth (USAR) — William Blair downgraded the stock to Market Perform.

VersaBank (VBNK) — Roth Capital maintained its Buy rating and revised its price target from $28.00 to $32.00.

Viking (VIK) — Mizuho upgraded the stock to Outperform, with a price target of $120.00.

Telefonica Brasil (VIV) — UBS Group upgraded the stock to Neutral.

Vivmark Residential Common Shares of Beneficial Interest (VMRK) — Royal Bank Of Canada raised its price target from $67.00 to $68.00, maintaining a Sector Perform rating.

Corporacion Inmobiliaria Vesta (VTMX) — UBS Group raised its price target from $43.00 to $47.00, maintaining a Buy rating.

Ventas (VTR) — Mizuho lowered its price target from $104.00 to $101.00, maintaining an Outperform rating.

Ventas (VTR) — Wells Fargo & Company raised its price target from $96.00 to $102.00, maintaining an Overweight rating.

Welltower (WELL) — Wells Fargo & Company raised its price target from $268.00 to $283.00, maintaining an Overweight rating.

Welltower (WELL) — Mizuho raised its price target from $260.00 to $270.00, maintaining an Outperform rating.

Western Midstream Partners (WES) — Wells Fargo & Company raised its price target from $46.00 to $47.00, maintaining an Equal Weight rating.

W.P. Carey (WPC) — Wells Fargo & Company raised its price target from $73.00 to $74.00, maintaining an Overweight rating.

Wise Group (WSE) — JPMorgan Chase & Co. raised its price target from $17.70 to $17.80, maintaining an Overweight rating.

Williams-Sonoma (WSM) — Telsey Advisory Group set a price target of $285.00, maintaining an Outperform rating.

Watsco (WSO) — Morgan Stanley raised its price target from $330.00 to $340.00, maintaining an Equal Weight rating.

Willis Towers Watson Public (WTW) — Morgan Stanley raised its price target from $325.00 to $350.00, maintaining an Equal Weight rating.

WhiteFiber (WYFI) — Cantor Fitzgerald lowered its price target from $36.00 to $24.00, maintaining an Overweight rating.

X-Energy (XE) — Piper Sandler raised its price target from $8.00 to $9.00, maintaining an Underweight rating.

DENTSPLY SIRONA (XRAY) — UBS Group lowered its price target from $17.00 to $13.00, maintaining a Buy rating.

Yarrow Bioscience (YARW) — Jefferies Financial Group set a price target of $40.00, maintaining a Buy rating.

YETI (YETI) — The Goldman Sachs Group downgraded the stock to Neutral and revised its price target from $57.00 to $41.00.

York Space Systems (YSS) — Citigroup lowered its price target from $10.00 to $8.00, maintaining a Buy rating.

York Space Systems (YSS) — Canaccord Genuity Group upgraded the stock to Buy and revised its price target from $13.50 to $9.00.

Zimmer Biomet (ZBH) — BMO Capital Markets lowered its price target from $102.00 to $101.00, maintaining a Market Perform rating.

Zimmer Biomet (ZBH) — Stifel Nicolaus raised its price target from $125.00 to $140.00, maintaining a Buy rating.

Zevra Therapeutics (ZVRA) — Guggenheim lowered its price target from $23.00 to $18.00, maintaining a Buy rating.

Join the discussion

Your email address will not be published. Required fields are marked *